Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease
References (30)
- et al.
Arterial walls are protected against deposition of platelet thrombi by a substance /Prostaglandin X/ which they make from prostaglandin endoperoxides
Prostaglandins
(1976) - et al.
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance /Prostaglandin X/ which prevents platelets aggregation
Prostaglandins
(1976) - et al.
Effect of prostacyclin /PGI2/ on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans
Pharmacol. Res. Commun.
(1982) - et al.
Prostacyclin and the fibrinolytic system in ischemic vascular disease
Thromb. Res.
(1983) - et al.
Successful therapy of advanced arteriosclerosis obliterans with Prostacyclin
Lancet
(1979) - et al.
Epoprostenol /prostacyclin/ and severe arterial disease
Lancet
(1983) - et al.
Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study
Thromb. Res.
(1985) - et al.
A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin
Blood
(1975) - et al.
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
Thromb. Res.
(1983) - et al.
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
Blood
(1984)
The effects of intravenous ZK 36–374, a stable prostacyclin analogue on normal volunteers
Prostaglandins
The fibrinolytic response of man to vasoactive drugs measured in arterial blood
Thromb. Res.
Beta-pyridylcarbinol /Ronicol/ releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans
Pharmacol. Res. Commun.
Prostaglandins in therapy of cardiovascular disease
Treatment of pulmonary embolism with prostacyclin
Surgery
Cited by (55)
Early Use of Iloprost in Nonfreezing Cold Injury
2022, Wilderness and Environmental MedicineCitation Excerpt :Already a recognized treatment of acute frostbite, iloprost is a synthetic prostaglandin I2 analogue with vasodilatory properties.4 It has an inhibitory effect on platelet aggregation and also stimulates release of endogenous tissue plasminogen activator, resulting in a thrombolytic effect.5 The intravenous infusion is started at 0.5 mcg·kg·min-1, incrementally increased every 30 min by 0.5 mcg·kg·min-1, up to a maximum of 2 mcg·kg·min-1.
The role of fibrinogen and fibrinolysis in peripheral arterial disease
2008, Thrombosis ResearchCitation Excerpt :Hematocrit, platelet count and fibrinogen levels were not modified during prostacyclin infusion [83]. Prostacyclin and its stable synthetic analog, iloprost, enhance fibrinolytic activity in PAD by releasing or facilitating the release of t-PA from the vessel wall [84]. Additionally, both short- and long-term treatment with iloprost significantly reduces PAI-1 Act, while long-term treatment significantly increases walking distance [85].
Regulation of Plasmin-dependent Fibrin Clot Lysis by Annexin II Heterotetramer
2001, Journal of Biological ChemistryIntermittent pneumatic compression devises - Physiological mechanisms of action
2001, European Journal of Vascular and Endovascular SurgeryTreatment of severe frostbite with Iloprost in Northern Canada
2016, CMAJCitation Excerpt :Alteplase is a recombinant tissue plasminogen activator. With its thrombolytic properties, it reverses the small-vessel thrombosis that occurs in frostbite and helps to restore perfusion to frostbitten digits.12 In the published studies,2–4 alteplase was associated with a decrease in the rate of amputation of severely frostbitten digits.